Naoya Kato

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography†

Ryota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida et al. · Hepatology · 2009 · 439 citations · Full text

Medicine, Oncology, Diagnostic Imaging +16

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma

Vinod Kumar, Naoya Kato, Yuji Urabe et al. · Nature Genetics · 2011 · 371 citations

Medicine, Genetics, Molecular Genetics +16

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 334 citations

Medicine, Oncology, Chemotherapy +7